MPC1L inhibitors encompass a range of chemical entities that target the mitochondrial pyruvate carrier 1 like protein through various biochemical pathways and mechanisms. One approach to inhibiting MPC1L function is through the modulation of gene expression; for example, histone deacetylase inhibitors can indirectly lead to decreased transcription of MPC1L. On the other hand, pyruvate dehydrogenase kinase inhibitors indirectly reduce MPC1L activity by shifting pyruvate utilization towards the pyruvate dehydrogenase complex, thereby diminishing the need for its import into the mitochondria through MPC1L. Direct inhibition occurs with compounds that specifically block the mitochondrial pyruvate carrier, completely shutting down MPC1L's ability to transport pyruvate into the mitochondria for metabolic processing. Additionally, chemicals that induce cellular stress or alter DNA integrity can trigger metabolic shifts that ultimately reduce the functional necessity for MPC1L, as cells adapt to changes in energy production and substrate availability.
Compounds that act on monocarboxylate transporters cause a buildup of pyruvate outside the mitochondria, which subsequently reduces the demand for MPC1L-mediated pyruvate transport. Inhibitors of ATP synthase like oligomycin disrupt the mitochondrial membrane potential, leading to a decreased requirement for the TCA cycle substrates and thus less need for MPC1L activity. Other inhibitors uncouple oxidative phosphorylation, resulting in a reduced ATP production and an altered cellular energy state that diminishes the role of MPC1L. Moreover, metabolic modulators such as PPAR-gamma agonists shift glucose metabolism away from mitochondrial pathways, which indirectly decreases the reliance on MPC1L for pyruvate handling. Glycolysis inhibitors like 2-deoxy-D-glucose reduce pyruvate production, while dichloroacetate's activation of the pyruvate dehydrogenase complex can bypass the need for MPC1L-mediated import. Finally, stress inducers such as sodium arsenite and differentiation modulators like retinoic acid can lead to metabolic reprogramming that lessens the importance of MPC1L in cellular metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sodium phenylbutyrate | 1716-12-7 | sc-200652 sc-200652A sc-200652B sc-200652C sc-200652D | 1 g 10 g 100 g 1 kg 10 kg | $77.00 $166.00 $622.00 $5004.00 $32783.00 | 43 | |
This compound acts as a histone deacetylase inhibitor, modulating gene expression. By altering gene expression patterns, sodium phenylbutyrate can influence the cellular metabolic profile, potentially decreasing the abundance or activity of MPC1L by reducing its transcription. | ||||||
UK 5099 | 56396-35-1 | sc-361394 sc-361394A | 10 mg 50 mg | $236.00 $987.00 | 5 | |
This compound is a specific inhibitor of the mitochondrial pyruvate carrier. By blocking pyruvate transport into the mitochondria, UK 5099 directly inhibits the activity of MPC1L, preventing pyruvate from entering the mitochondrial matrix where it is metabolized. | ||||||
α-Cyano-4-hydroxycinnamic acid | 28166-41-8 | sc-254923 | 2 g | $43.00 | 2 | |
This compound inhibits the monocarboxylate transporters, which may lead to an accumulation of pyruvate outside the mitochondria. Such accumulation can indirectly inhibit MPC1L by decreasing the gradient-driven demand for mitochondrial pyruvate import. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
As an ATP synthase inhibitor, this compound disrupts the mitochondrial membrane potential. This disruption can lead to a decreased demand for substrates by the TCA cycle, thereby potentially reducing the functional necessity for MPC1L activity. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Uncouples oxidative phosphorylation, leading to reduced ATP production and altered mitochondrial function. This change can downregulate the cellular need for MPC1L-mediated pyruvate import into the mitochondria due to a lesser requirement for substrates in the TCA cycle. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
A PPAR-gamma agonist that modulates glucose and lipid metabolism. Activation of PPAR-gamma can lead to an increased uptake and utilization of glucose by alternative pathways, potentially diminishing the requirement for MPC1L function in pyruvate transport to mitochondria. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A glucose analog that inhibits glycolysis. By inhibiting glycolysis, 2-deoxy-D-glucose can reduce the production of pyruvate, indirectly decreasing the need for MPC1L-mediated transport into mitochondria. | ||||||
Dichloroacetic acid | 79-43-6 | sc-214877 sc-214877A | 25 g 100 g | $61.00 $128.00 | 5 | |
An inhibitor of pyruvate dehydrogenase kinase, this compound activates the pyruvate dehydrogenase complex, which could lead to an increased conversion of pyruvate to acetyl-CoA, potentially bypassing the requirement for MPC1L in pyruvate mitochondrial import. | ||||||
Sodium (meta)arsenite | 7784-46-5 | sc-250986 sc-250986A | 100 g 1 kg | $108.00 $780.00 | 3 | |
Induces stress responses and affects mitochondrial function. The resulting stress and alterations in cellular metabolism can downregulate the demand for pyruvate transport via MPC1L into the mitochondria. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
As a modulator of gene expression through retinoid receptors, retinoic acid can shift cellular metabolism and differentiation states, which may lead to a reduced requirement for MPC1L due to changes in metabolic pathway usage. | ||||||